Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neuroendocrine Tumors × tremelimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Colorectal Neoplasms 7 Prostatic Neoplasms 6 Diabetes Mellitus, Insulin-Dependent, 12 6 Melanoma 5 Carcinoma, Non-Small-Cell Lung 5 Carcinoma, Hepatocellular 5 Breast Neoplasms 5 Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Recurrence 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Urinary Bladder Neoplasms 2 Recurrent Squamous Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Mesothelioma 2 Lung Neoplasms 2 Liver Neoplasms 2 Fallopian Tube Neoplasms 2 Cholangiocarcinoma 2 Biliary Tract Neoplasms 2 Vascular Neoplasms 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Testicular Neoplasms 1 Solid Tumor 1 Sarcoma, Synovial 1

Interventions

Everolimus 13 Octreotide 6 Magnetic Resonance Spectroscopy 5 lanreotide 4 Sunitinib 4 gallium Ga 68 dotatate 3 cabozantinib 3 arginyllysine 3 Specimen Handling 3 Nivolumab 3 Etoposide 3 Carboplatin 3 Bevacizumab 3 telotristat ethyl 2 surufatinib 2 pembrolizumab 2 pazopanib 2 pasireotide 2 lutetium Lu 177 dotatate 2 X-Rays 2 Temozolomide 2 Phantoms, Imaging 2 Oxaliplatin 2 Ipilimumab 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Cisplatin 2 Capecitabine 2 3-Iodobenzylguanidine 2 177Lu-DOTA-JR11 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡